Director Dealing and Total Voting Rights

RNS Number : 1111C

Proteome Sciences PLC

11 April 2017

 

Proteome Sciences plc

(the "Company" or the "Group")

Director Dealing and Total Voting Rights

Proteome Sciences plc (AIM:PRM) announces that on 7 April 2017, Ian Pike, Chief Scientific Officer of the Company and a former employee exercised 165,583 and 158,308 options over ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") respectively.

Application has been made to the London Stock Exchange for the 323,891 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 18 April 2017.

After Admission, the total number of Ordinary Shares in issue will be 294,648,723, all with voting rights. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information: Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer                          Tel: [phone]
Dr Ian Pike, Chief Scientific Officer
Geoff Ellis, Finance Director
finnCap Limited (Nominated Adviser/Broker) Geoff Nash/James Thompson	Tel: [phone]
Tony Quirke (broking) IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Herring/Miles Nolan	Tel: [phone]

Notes for editors:

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant^®, TMTcalibrator^™) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in London, UK and in Frankfurt, Germany from where the PS Biomarker Services^™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Ian Pike
2.	Reason for the Notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Proteome Sciences plc
b)	LEI	n/a
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Options over Ordinary Shares of 1p each
	Identification code	GB0003104196
b)	Nature of the transaction	Exercise of options
c)	Price(s) and volume(s)	165,583 options
d)	Aggregated information: ·      Aggregated volume ·      Price	165,583 Options over Ordinary Shares of 1p each exercised
e)	Date of the transaction	7 April 2017
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

 

END

 

 

MSCFMGMDKGZGNZM